Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713670 | 0.92 | PTGS2 (0.51) | PTGS2PTGDR2METAP2NPBWR1LOXL2 | |
| SCHEMBL23627360 | 0.82 | PTGS2 (0.48) | PTGS2PTGDR2 | |
| SCHEMBL20032127 | 0.78 | LOXL2 (0.34) | LOXL2 | |
| SCHEMBL20032433 | 0.77 | PTGDR2 (0.38) | PTGDR2 | |
| SCHEMBL8680609 | 0.76 | ADORA3 (0.37) | — | |
| SCHEMBL20032129 | 0.74 | CTSS (0.43) | PTGS2METAP2LOXL2 | |
| SCHEMBL23095478 | 0.73 | CTSS (0.40) | METAP2LOXL2 | |
| SCHEMBL20032468 | 0.72 | PTGS2 (0.53) | PTGS2PTGDR2 | |
| SCHEMBL23846698 | 0.72 | SMN1; SMN2 (0.50) | PTGS2 | |
| SCHEMBL20032444 | 0.72 | RORC (0.41) | PTGS2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PTGS2 645/4885PTGDR2 872/4885METAP2 1452/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PTGS2 645/4885PTGDR2 872/4885METAP2 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.